Rion reposted this
We are thrilled to announce the initiation of our Phase 1b clinical trial evaluating Purified Exosome Product™ (PEP™) for knee osteoarthritis, a groundbreaking step in the field of regenerative medicine. As the first FDA-approved study to evaluate therapeutic exosomes in orthopedics, this trial represents a pivotal moment for both RION and the future of knee osteoarthritis treatment. The trial will involve 24 patients across the U.S. in a randomized, open-label study, focusing on the safety and early efficacy of PEP™ for Knee OA. Patients will receive single intra-articular injections of PEP™, aimed at providing relief to the 364 million people affected globally by this debilitating condition. At RION, our mission is to transform patient care through innovative exosome technology. Built on decades of research, our proprietary PEP™ platform is designed to address the unmet needs of chronic conditions like Knee OA. Learn more about this groundbreaking trial and the potential of our PEP™ technology by clicking the link below. https://lnkd.in/ecgNTcd7